Bio-Rad Laboratories, Inc. Class A Common Stock vs Emerson Electric Co. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $355.23 (market cap $9.43B), while Emerson Electric Co. trades at $163.54 (market cap $91.69B). The key difference: Emerson Electric Co. is far larger — about 9.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Emerson Electric Co. pays a 1.35% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | EMR | |
|---|---|---|
Market Cap | $9.43B | $91.69B |
Sector | Health | Industrials |
52-Week High | $356.25 | $164.38 |
52-Week Low | $241.71 | $123.30 |
Enterprise Value | $9.18B | $102.77B |
Dividend Yield | — | 1.35% |
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Emerson Electric (EMR) trades at $158.69, up 0.27% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.71 exceeding expectations, supported by 7% revenue growth and expanding margins. Recent acquisition of Glue Inc. enhances AI capabilities while dividend payments provide shareholder returns.
Outlook remains positive with raised 2026 guidance and $171.33 consensus price target offering 8% upside. Key risks include valuation at 36x P/E and cyclical exposure to industrial markets. Institutional support remains strong with 53.7% buy ratings, though RSI levels suggest potential near-term consolidation.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →